This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

SunLink Health Systems, Inc. Announces Fiscal 2012 First Quarter Results

SunLink Health Systems, Inc. (NYSE Amex Equities: SSY) today announced a loss from continuing operations for its first fiscal quarter ended September 30, 2011 of $305,000, or a loss of $0.04 per fully diluted share, compared to a loss from continuing operations of $2,263,000, or a loss of $0.28 per fully diluted share for the quarter ended September 30, 2010.

SunLink reported a net loss of $318,000, or a loss of $0.04 per fully diluted share for the quarter ended September 30, 2011, compared to a net loss of $2,768,000, or $0.34 per fully diluted share for the comparable quarter a year ago.

Consolidated net revenues from continuing operations for the quarters ended September 30, 2011 and 2010 were $43,053,000 and $40,866,000, respectively, an increase of 5.4% in the current year’s quarter. The Healthcare Facilities Segment net revenues in the current quarter of $35,298,000 increased $3,334,000, or 10.4%, compared to $31,964,000 from the prior year. Net revenues from the Medicare and Medicaid Electronic Health Records Incentive Programs in the current year were $2,998,000. The Specialty Pharmacy Segment revenues of $7,755,000 in the quarter ended September 30, 2011 decreased 12.9% from the prior year.

The company had an operating profit for the quarter ended September 30, 2011 of $811,000, compared to an operating loss for the quarter ended September 30, 2010 of $2,109,000, an increase in the operating margin of $2,920,000 in the current year quarter. EBITDA (a non-GAAP measure of liquidity of the company) for the first fiscal quarter was $2,115,000 compared to an EBITDA loss of $516,000 for the comparable quarter a year ago. Adjusted EBITDA for SunLink’s Healthcare Facilities Segment in the fiscal quarter ended September 30, 2011 increased to $3,259,000 from $458,000 in the comparable quarter a year ago. Adjusted EBITDA for SunLink’s Specialty Pharmacy Segment was a loss of $46,000 in the first fiscal quarter compared to Adjusted EBITDA of $183,000 in the comparable quarter a year ago.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs